STVN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

333.80M

+0.97%

0.196

-4.48%

274.17M

+6.85%

0.129

+13.29%

305.04M

+8.94%

0.165

+29.79%

Estimates Revision

The market is revising Upward the revenue expectations for Stevanato Group S.p.A. (STVN) for FY2025, with the revenue forecasts being adjusted by 0.14% over the past three months. During the same period, the stock price has changed by -11.70%.

Revenue Estimates for FY2025

Revise Upward

+0.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.02%

In Past 3 Month

Stock Price

Go Down

-11.70%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast STVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STVN is 28.00 USD with a low forecast of 26.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

26.00

Averages

28.00

High

30.00

Current: 0.000

Low

26.00

Averages

28.00

High

30.00

KeyBanc

maintain

$200 basis points

2025-12-24

Reason

KeyBanc

Price Target

$200 basis points

2025-12-24

maintain

Reason

KeyBanc believes the risk to oral weight loss drugs remains limited to 2030 from the approval of Wegovy's oral version. Oral GLP-1 market penetration will remain capped in the near and long term despite new market approvals, the analyst tells investors in a research note. KeyBanc believes the oral version of Wegovy will only contribute 200 basis points to overall GLP-1 market share by 2030. The firm thinks GLP-1 suppliers are likely conservative with their market assumptions. West Pharmaceutical (WST) and Stevanato Group (STVN) have both commented on their market assumption that orals will have 30% market share of the overall GLP-1 market, it notes. KeyBanc expects both suppliers to continue to ramp as the market launches next-generation GLP-1s in injectable format.

Morgan Stanley

Tejas Savant

Equal Weight

maintain

$24 -> $26

2025-11-11

Reason

Morgan Stanley

Tejas Savant

Price Target

$24 -> $26

2025-11-11

maintain

Equal Weight

Reason

Morgan Stanley analyst Tejas Savant raised the firm's price target on Stevanato Group to $26 from $24 and keeps an Equal Weight rating on the shares.

UBS

John Sourbeer

Hold

Maintains

$24 → $24

2025-03-07

Reason

UBS

John Sourbeer

Price Target

$24 → $24

2025-03-07

Maintains

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Stevanato Group SpA (STVN.N) is 30.30, compared to its 5-year average forward P/E of 38.50. For a more detailed relative valuation and DCF analysis to assess Stevanato Group SpA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

38.50

Current PE

30.30

Overvalued PE

46.56

Undervalued PE

30.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

19.87

Current EV/EBITDA

15.70

Overvalued EV/EBITDA

24.05

Undervalued EV/EBITDA

15.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.10

Current PS

3.86

Overvalued PS

6.09

Undervalued PS

4.12

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

STVN News & Events

Events Timeline

No data

News

3.0

2025-12-19NASDAQ.COM

SDZNY vs. STVN: Which Stock Offers Better Value?

4.5

2025-12-11Barron's

S&P 500 Futures Drop in Pre-Market Session; Oracle and Stellantis Underperform

2.0

2025-12-03NASDAQ.COM

Stevanato Group SpA Surpasses 200-Day Moving Average - Positive Outlook for STVN

People Also Watch

Frequently Asked Questions

What is Stevanato Group SpA (STVN) stock price today?

The current price of STVN is 21.06 USD — it has decreased -3.92 % in the last trading day.

What is Stevanato Group SpA (STVN)'s business?

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

What is the price predicton of STVN Stock?

What is Stevanato Group SpA (STVN)'s revenue for the last quarter?

Stevanato Group SpA revenue for the last quarter amounts to 303.17M USD, increased 9.11 % YoY.

What is Stevanato Group SpA (STVN)'s earnings per share (EPS) for the last quarter?

Stevanato Group SpA. EPS for the last quarter amounts to 0.13 USD, increased 18.18 % YoY.

What changes have occurred in the market's expectations for Stevanato Group SpA (STVN)'s fundamentals?

How many employees does Stevanato Group SpA (STVN). have?

Stevanato Group SpA (STVN) has 5521 emplpoyees as of January 10 2026.

What is Stevanato Group SpA (STVN) market cap?

Today STVN has the market capitalization of 5.75B USD.